Albioma : Buying pressure
Entry price | Target | Stop-loss | Potential |
---|
€44.34 |
€49.84 |
€42.74 |
+12.4% |
---|
Albioma shares have been in strong demand lately. The technical chart pattern looks positive which may give rise to new gains.
Strengths● The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
● Analysts covering this company mostly recommend stock overweighting or purchase.
● Considering the small differences between the analysts' various estimates, the group's business visibility is good.
● Historically, the company has been releasing figures that are above expectations.
Weaknesses● The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
● The firm trades with high earnings multiples: 24.43 times its 2021 earnings per share.
● The company's enterprise value to sales, at 4 times its current sales, is high.
● The company is highly valued given the cash flows generated by its activity.
● The average consensus view of analysts covering the stock has deteriorated over the past four months.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.